Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers
- 1 January 2022
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 228, 114040
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFCancer Research, 2018
- Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersJournal of Medicinal Chemistry, 2017
- LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerOncotarget, 2016
- RAF inhibitors that evade paradoxical MAPK pathway activationNature, 2015
- BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal CancersMolecular Cancer Therapeutics, 2015
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersCancer Cell, 2015
- Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNature Reviews Cancer, 2014
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant TumorsCancer Cell, 2014
- Kinases and Pseudokinases: Lessons from RAFMolecular and Cellular Biology, 2014
- A dimerization-dependent mechanism drives RAF catalytic activationNature, 2009